Cancer clinical trials in the region Occitanie
292 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2 / Phase 3
Pancreas cancer
#NCT07076121
#2025-522598-12-00
Adenocarcinoma
Metastatic
MTAP
None
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Toulouse (Toulouse)
Bristol-Myers Squibb
Phase 2 / Phase 3
Colon cancer
Rectal cancer
#NCT05462613
#2024-516709-22-00
Metastatic
1
Surgery
Chemotherapy
Targeted therapy
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
CHU de Besançon
Phase 2 / Phase 3
Pancreas cancer
#NCT05254171
#2024-514714-12-00
Adenocarcinoma
Metastatic
None
Systemic Treatment-Naive
BRCA 1/2
Centre Hospitalier Universitaire de Toulouse (Toulouse)
Panbela Therapeutics Inc
Phase 2 / Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06225596
#2023-504231-41-01
Urothelial carcinoma
Locally Advanced
Metastatic
Institut du cancer de Montpellier (Montpellier)
BicycleTx Limited
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
B cell lymphoma
Mantel cell lymphoma
Early (stage I and II)
Disseminated (stage III and IV)
None
> 60 ml/min
50-60 ml/min
30-50 ml/min
1
2
3 or more
Targeted therapy
Bispecific T-cell engager antibodies
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
B cell lymphoma
Mantel cell lymphoma
Early (stage I and II)
Disseminated (stage III and IV)
None
> 60 ml/min
50-60 ml/min
30-50 ml/min
1
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
B cell lymphoma
Mantel cell lymphoma
Early (stage I and II)
Disseminated (stage III and IV)
None
> 60 ml/min
50-60 ml/min
30-50 ml/min
None
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Endometrial cancer
#NCT06906341
#2024-517432-21-00
Stage III
Stage IV
Locally Advanced
Metastatic
1
2
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Toulouse (Toulouse)
Corcept Therapeutics
Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06760819
#2024-517419-62-00
Stomach
Oesogastric junction
Esophagus
Adenocarcinoma
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Ampullary carcinoma
Gastrointestinal stromal tumor
Squamous cell carcinoma
Other
HER2 Positive
Locally Advanced
Metastatic
Metastatic Castration-resistant
HER2
1
Systemic Treatment-Naive
Institut du cancer de Montpellier (Montpellier)
Bayer
Phase 2
Liver and bile duct cancer
#NCT06904170
#2024-514912-28-00
Hepatocellular carcinoma
Unhealthy
A
None
Systemic Treatment-Naive
Systemic Treatment-Naive
Transarterial chemoembolization
Centre Hospitalier Universitaire de Toulouse (Toulouse)
UNICANCER